MSE
SRPT icon

MUFG Securities EMEA’s Sarepta Therapeutics SRPT Stock Holding History

MUFG Securities EMEA’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-20,999
Closed -$1.34M – 562
2025
Q1 		$1.34M Sell
20,999
-58,001
-73% -$6.11M 0.03% 116
2024
Q4 		$9.61M Buy
+79,000
New +$9.68M 0.16% 88
2024
Q3 		– Sell
-37,900
Closed -$5.99M – 190
2024
Q2 		$5.99M Buy
+37,900
New +$4.87M 0.26% 60
2020
Q3 		– Sell
-55,000
Closed -$8.82M – 459
2020
Q2 		$8.82M Buy
+55,000
New +$7.48M 0.08% 166

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

MUFG Securities EMEA's SRPT Position: Q2 2025 in Review

MUFG Securities EMEA sold out of Sarepta Therapeutics (SRPT) in Q2 2025, closing a stake of 20,999 shares — an estimated $1.34M sold.

MUFG Securities EMEA first reported a position in SRPT in Q2 2020 and held it in 4 quarters. The position peaked at $9.61M in Q4 2024. 362 funds tracked by Wall St. Rank hold SRPT as of Q2 2025.

  • MUFG Securities EMEA reported no remaining Sarepta Therapeutics position as of Q2 2025 after selling out during the quarter.
  • MUFG Securities EMEA sold 20,999 Sarepta Therapeutics shares in Q2 2025, an estimated $1.34M.
  • MUFG Securities EMEA first reported a position in Sarepta Therapeutics in Q2 2020 and held it in 4 quarters.
  • MUFG Securities EMEA's Sarepta Therapeutics position peaked at $9.61M in Q4 2024.
  • 362 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2025.

Based on MUFG Securities EMEA's 13F filing for Q2 2025, filed 5 Aug 2025.